Skip to content

Study in Pediatric Volunteers of a Handheld Device Versus a Standard Diagnostic Device in Ophthalmic Refraction

An Exploratory Study in Healthy Pediatric Volunteers to Evaluate the Performance of a Handheld Device Compared With Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04955379
Enrollment
50
Registered
2021-07-08
Start date
2021-12-15
Completion date
2023-07-31
Last updated
2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Accomodation, Diagnostic Self Evaluation, Refractive Errors

Keywords

Refraction, Telehealth, Vision, Accommodation

Brief summary

This study is exploratory and examines whether the refraction results obtained from a novel optical device yields results similar to the ophthalmic refraction measurements obtained from an autorefractor in children.

Detailed description

This study is exploratory and examines whether the refraction results obtained from a novel optical device yields results similar to the ophthalmic refraction measurements obtained from an autorefractor in the age stratum of 6 through 17 years.

Interventions

DEVICEEQ103

Ophthalmic Refractometer with a measurement and background channel

Sponsors

Sheba Medical Center
CollaboratorOTHER_GOV
EyeQue Corp.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or Female * Ages ≥6 y.o. and \<18 y.o. * Binocular vision * Parent(s) or Guardian(s) willing and able to give informed consent on behalf of the subject. * Subject able to follow all study procedures and requirements

Exclusion criteria

* Spherical correction \> +8 or \< -10 * Using anticholinergic medications (including first-generation antihistamines) or other medications known to affect visual acuity within the greater of 3 days or 5 half-lives prior to enrolling in this study. * Using an investigational drug or approved therapy for investigational use within the greater of 3 days or 5 half-lives prior to enrolling in this study. * Has initiated any new medication in the past 2 weeks that, in the best medical judgment of the investigator, would impact their participation in the study or ability to use the EyeQue EQ103 device, * Any self/caregiver-reported mental illness or condition of the subject, including but not limited to claustrophobia, fear of simulators, nyctophobia. * Any self/caregiver-reported neurological diseases of the subject, including but not limited to: epilepsy, nystagmus. * Any self/caregiver-reported glaucoma diagnosis of the subject. * Eye disease, including but not limited to: * Cataracts * Macular degeneration * Eye infection (by self-report or observation) * Keratoconus * Diabetic neuropathy/retinopathy * Cytomegalovirus retinitis * Color blindness (any color deficiency) * Diabetic macular edema * Amblyopia * Chronic or acute uveitis * Strabismus * Astigmatism \> 3 diopters * Macular hole * Lack physical dexterity to properly operate the EyeQue device. * Lack the ability to follow instruction. * Lack binocular vision. * Are colorblind. * Had eye surgery within the last 12 months.

Design outcomes

Primary

MeasureTime frameDescription
Tendency of, or achieving, statistical equivalence of refraction measurements EQ103 (non-cycloplegic) compared with autorefractor (non-cycloplegic)Day 1Tendency of, or achieving, statistical equivalence of refraction measurements EQ103 (non-cycloplegic) compared with autorefractor (non-cycloplegic)

Secondary

MeasureTime frameDescription
EyeQue EQ103 (non-cycloplegic) and the autorefractor (cycloplegic) assessed by refractive error measured by each device analyzed by age-strata.Day 1 and 14EyeQue EQ103 (non-cycloplegic) and the autorefractor (cycloplegic) assessed by refractive error measured by each device analyzed in the following age-strata. Age Groups * 6 to 12 y.o. \>12 to \<18 y.o.
EQ103 without cycloplegia will be compared to EQ103 with cycloplegia by younger age-strata.Day 1 and 14EQ103 without cycloplegia will be compared to EQ103 with cycloplegia in the following age-strata. Age Group * 6 to 12 y.o.

Countries

Israel

Contacts

Primary ContactNoam Sapiens, PhD
noam.sapiens@eyeque.com(510) 953-6433
Backup ContactYgal Rotenstreich
(408) 630-5086

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026